Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair® ).

Abstract

Omalizumab (Xolair® ) is an anti-IgE monoclonal antibody, which may benefit adults with systemic mastocytosis. We report effective treatment with omalizumab in two toddlers with severe diffuse cutaneous mastocytosis. Our cases offer preliminary evidence to support the safe use of omalizumab in paediatric patients with cutaneous mastocytosis.

• Authors: J D M Hughes, T Olynyc, H Chapdelaine, L Segal, B Miedzybrodzki, M Ben-Shoshan
• Journal: Clinical and experimental dermatology (Clin Exp Dermatol) Vol. 43 Issue 5 Pg. 573-576 (Jul 2018) ISSN: 1365-2230 [Electronic] England
• PMID: 29451318 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2018 British Association of Dermatologists.

Chemical References

• Anti-Allergic Agents
• Omalizumab

Topics

• Anti-Allergic Agents (therapeutic use)
• Child, Preschool
• Humans
• Male
• Mastocytosis, Cutaneous (drug therapy)
• Omalizumab (therapeutic use)